1. Sucrosomial® Iron Supplementation in Mice: Effects on Blood Parameters, Hepcidin, and Inflammation
   Michela Asperti et al, 2018, Nutrients CrossRef
2. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update
   Julia Bohlius et al, 2019, Blood Advances CrossRef
3. Sucrosomial Iron Supplementation in Anemic Patients with Celiac Disease Not Tolerating Oral Ferrous Sulfate: A Prospective Study
   Luca Elli et al, 2018, Nutrients CrossRef
4. Improved patient blood management and cost saving in hip replacement surgery through the implementation of pre-operative Sucrosomial® iron supplementation: a quality improvement assessment study
   Marco Scardino et al, 2019, International Orthopaedics CrossRef
5. Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation
   Susana Gómez-Ramírez et al, 2018, Pharmaceuticals CrossRef
6. Monitoring oral iron therapy in children with iron deficiency anemia: an observational, prospective, multicenter study of AIEOP patients (Associazione Italiana Emato-Oncologia Pediatrica)
   Giovanna Russo et al, 2020, Annals of Hematology CrossRef
7. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update
   Julia Bohlius et al, 2019, Journal of Clinical Oncology CrossRef
8. Iron Support in Erythropoietin Treatment in Myelodysplastic Syndrome Patients Affected by Low-Risk Refractory Anaemia: Real-Life Evidence from an Italian Setting
   Giulio Giordano et al, 2020, Acta Haematologica CrossRef
9. Iron Supplementation in Suckling Piglets: An Ostensibly Easy Therapy of Neonatal Iron Deficiency Anemia
   Mateusz Szudzik et al, 2018, Pharmaceuticals CrossRef
10. Innovative oral sucrosomial ferric pyrophosphate-based supplementation rescues suckling piglets from iron deficiency anemia similarly to commonly used parenteral therapy with iron dextran
    Mateusz Szudzik et al, 2021, Annals of Animal Science CrossRef
11. Epoetin alfa biosimilar (HX575): A review of 15 years’ post-approval clinical experience
    Pere Gascón et al, 2023, Critical Reviews in Oncology/Hematology CrossRef
12. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study
    Antonino Mafodda et al, 2017, Supportive Care in Cancer CrossRef
13. Direct healthcare costs of chronic kidney disease management in Italy: What cost‐savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis‐stimulating agents?
    Ylenia Ingrasciotta et al, 2021, Pharmacoepidemiology and Drug Safety CrossRef
14. Position paper on management of iron deficiency in adult cancer patients
    Sandro Barni et al, 2017, Expert Review of Hematology CrossRef
15. Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis
    Jichun Yang et al, 2019, BioDrugs CrossRef
16. Budget Impact Analysis of Oral Fisiogen Ferro Forte® versus Intravenous Iron for the Management of Iron Deficiency in Chronic Kidney Disease in Spain
    Josep Darbà et al, 2018, Clinical Drug Investigation CrossRef
17. Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy
    Ylenia Ingrasciotta et al, 2019, BioDrugs CrossRef
18. Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments
    Michela Asperti et al, 2021, American Journal of Hematology CrossRef